Kessler Topaz Meltzer & Check, LLP Alerts IBRX Investors on Class Action Lawsuit Options
In a significant development for investors of ImmunityBio, Inc. (NASDAQ: IBRX), Kessler Topaz Meltzer & Check, LLP, a well-known law firm specializing in securities litigation, has announced a class action lawsuit against the company. The lawsuit pertains to those who purchased or acquired IBRX securities between January 19, 2026, and March 24, 2026. Investors affected by this litigation are encouraged to contact the firm to discuss their rights and potential actions.
The securities fraud class action has been initiated in the United States District Court for the Central District of California under the case title Douglas v. ImmunityBio, Inc., with the case number 226-cv-03261. This legal action comes in light of allegations that ImmunityBio made materially false and misleading statements about its lead biologic product, Anktiva. The allegations underscore the company's failure to disclose significant risks and misrepresentations related to Anktiva’s effectiveness as a cancer vaccine.
The class period notably includes a critical timeframe where various claims about Anktiva were made by key executives of the company, including statements that overstated the product's capabilities and prospects. These claims have drawn scrutiny from investors who now find themselves engaging with the legal implications of potential fraud.
The situation escalated dramatically when, on March 24, 2026, Bloomberg reported the receipt of a Warning Letter from the FDA directed at ImmunityBio. The letter cited misleading statements made by the company’s Executive Chairman, Patrick Soon-Shiong, regarding Anktiva’s purported ability to cure and prevent all cancers. The FDA determined that the promotional materials related to Anktiva were not only misleading but also posed legal violations under the Federal Food, Drug, and Cosmetic Act. Following this revelation, ImmunityBio’s stock price plummeted by 21.12%, closing at $7.42 per share.
Affected investors who acquired ImmunityBio stocks during the specified class period have until May 26, 2026, to file for lead plaintiff status. This is crucial as the lead plaintiff acts on behalf of the entire class in the legal proceedings. Investors are urged to consider a variety of options including:
ImmunityBio investors who may have been misled or suffered losses as a result of these events are strongly advised to reach out to Kessler Topaz Meltzer & Check, LLP for a free case evaluation. This legal firm has a strong track record in securities class action lawsuits and is well-equipped to guide affected investors through the intricate process of seeking recovery for their losses. The upcoming deadline for filing a lead plaintiff status is especially critical, making prompt action essential for those impacted by ImmunityBio's recent challenges. For further details or to connect with a legal representative, interested parties should contact the firm directly.
For more information on Kessler Topaz Meltzer & Check, LLP, and updates on the ImmunityBio class action lawsuit, please visit www.ktmc.com or contact Jonathan Naji, Esq. at (484) 270-1453.
Background of the Case
The securities fraud class action has been initiated in the United States District Court for the Central District of California under the case title Douglas v. ImmunityBio, Inc., with the case number 226-cv-03261. This legal action comes in light of allegations that ImmunityBio made materially false and misleading statements about its lead biologic product, Anktiva. The allegations underscore the company's failure to disclose significant risks and misrepresentations related to Anktiva’s effectiveness as a cancer vaccine.
The class period notably includes a critical timeframe where various claims about Anktiva were made by key executives of the company, including statements that overstated the product's capabilities and prospects. These claims have drawn scrutiny from investors who now find themselves engaging with the legal implications of potential fraud.
Implications of the FDA Letter
The situation escalated dramatically when, on March 24, 2026, Bloomberg reported the receipt of a Warning Letter from the FDA directed at ImmunityBio. The letter cited misleading statements made by the company’s Executive Chairman, Patrick Soon-Shiong, regarding Anktiva’s purported ability to cure and prevent all cancers. The FDA determined that the promotional materials related to Anktiva were not only misleading but also posed legal violations under the Federal Food, Drug, and Cosmetic Act. Following this revelation, ImmunityBio’s stock price plummeted by 21.12%, closing at $7.42 per share.
Steps for Affected Investors
Affected investors who acquired ImmunityBio stocks during the specified class period have until May 26, 2026, to file for lead plaintiff status. This is crucial as the lead plaintiff acts on behalf of the entire class in the legal proceedings. Investors are urged to consider a variety of options including:
- - Consulting with legal counsel to explore potential claims.
- - Taking action to become lead plaintiffs while there is still time.
- - Engaging with Kessler Topaz Meltzer & Check, LLP, which operates on a contingency fee basis, meaning there are no upfront costs for litigating these claims.
Conclusion
ImmunityBio investors who may have been misled or suffered losses as a result of these events are strongly advised to reach out to Kessler Topaz Meltzer & Check, LLP for a free case evaluation. This legal firm has a strong track record in securities class action lawsuits and is well-equipped to guide affected investors through the intricate process of seeking recovery for their losses. The upcoming deadline for filing a lead plaintiff status is especially critical, making prompt action essential for those impacted by ImmunityBio's recent challenges. For further details or to connect with a legal representative, interested parties should contact the firm directly.
For more information on Kessler Topaz Meltzer & Check, LLP, and updates on the ImmunityBio class action lawsuit, please visit www.ktmc.com or contact Jonathan Naji, Esq. at (484) 270-1453.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.